Welcome to Livivos.

Liver Testing at the Point-of-Care.

Silent Disease.

An estimated 80 million Americans have Metabolic dysfunction-associated steatotic liver disease (MASLD), raising their risk of liver cancer, cirrhosis, and cardiovascular events.

Critical Liver Testing Need.

As new liver disease treatments are emerging, the demand for point-of-care diagnostic testing has intensified. These tests are essential for drug qualification and monitoring responses.

Quantifying Liver Fat.

The LiverScope® uses patented technology to measure liver steatosis and track changes during treatment. With new therapies emerging, the need for point-of-care liver testing is rapidly growing.

“The diagnosis of NASH can be difficult, as most patients in early stages of the disease have no symptoms. The identification of patients is currently not possible by a typical physical examination.”

The Wall Street Journal – A Big, Fatty Opportunity for Big Pharma.

“Signs of the disease are asymptomatic, so a person often is not diagnosed with NASH until it advances to a late stage, when cirrhosis begins to ravage the body”.

CNBC – The $35 billion race to cure a silent killer that affects 30 million Americans.

The Need for Effective Liver Tests.

Liver Disease Prevalence.

MASLD can progress to MASH (Metabolic Dysfunction-Associated Steatohepatitis) accompanied by advanced fibrosis, affecting approximately 3% of the global population. Alarmingly, liver disease claims the lives of 1.75 million individuals annually. The critical prevalence of fatty liver disease comes with an associated annual direct medical cost of over $100 billion, in the United States alone, with a significantly higher burden when societal costs are included.

Learn more

Improved Testing.

LiverScope® provides instant results, without the need for image interpretation or histological examination – overcoming critical deficiencies of standard diagnostic modalities.

Livivos’s technology transforms liver disease testing, responding to a fast-growing demand for effective and broadly available testing. LiverScope® will significantly advance liver testing on a larger scale and will support effective evaluation of the response to treatments.

Learn more

Point-of-Care Steatosis Quantification Benefits .

MASH Identification

Noninvasive identification of MASH is central to cost-effective disease management. For identification of hepatic steatosis, MRI-PDFF is the most sensitive access the spectrum of steatosis and is accurate to assess dynamic change.*

*AASLD Practice Guidance on The Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease; Rinella et al; Hepatology; 2023;77:1797-1835

Treatment Qualification

Resmetirom is designed to treat patients with greater than 8% steatosis. The LiverScope® MR-PDFF^TM technology was developed to offer point-of-care steatosis quantification, ensuring a low-cost and time-efficient solution for drug qualification.*

*LiverScope® is not for sale and limited by federal law to investigational use

Therapeutic Response Monitoring

A relative reduction in percent steatosis > 30% is the single best predictor of therapeutic response in both MASH resolution and fibrosis reduction.* Point-of-care , longitudinal PDFF testing on treatment enables early identification of drug non-responders.

*Harrison et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 2024;390:497-509.